Cancer cell senescence: a new frontier in drug development.
Senescence forms a universal block to tumorigenesis which impacts on all hallmarks of cancer, making it an attractive target for drug discovery. Therefore a strategy must be devised to focus this broad potential into a manageable drug discovery programme. Several issues remain to be addressed including the lack of robust senescence-inducing compounds and causally related biomarkers to measure cellular response. Here, we review the latest progress in translating senescence as a target for cancer therapy and some promising approaches to drug and biomarker discovery. Finally, we discuss the potential application of a senescence-induction therapy in a clinical setting.
Institute of Cancer Sciences, University of Glasgow, CRUK Beatson Laboratories, Bearsden, Glasgow, UK.
Claire J
CJ
Cairney
Alan E
AE
Bilsland
T R Jeffry
TR
Evans
Jon
J
Roffey
Dorothy C
DC
Bennett
Masashi
M
Narita
Christopher J
CJ
Torrance
W Nicol
WN
Keith
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D016922:Cellular Senescence / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor